Great Point Partners (GPP) has acquired a majority stake in Eutecma, a developer of reusable temperature-controlled packaging solutions for pharmaceutical cold chain logistics.
Established in 2008, Germany-based Eutecma has dedicated itself to developing passive cooling systems that enhance sustainability and efficiency in transportation and logistics.
It is said to have established itself in the pharmaceutical sector with its patented ICECATCH cooling systems.
Eutecma’s ‘retecma’ system fosters a circular economy for its packaging materials through an extensive network of refreshment centres.
The approach ensures that materials are kept in circulation for longer periods while minimising carbon dioxide emissions.
GPP vice-president Harrison Johnson said: “Eutecma has the opportunity to further expand its global capabilities at a time when there’s growing demand for reusability, cost savings, and new cooling technologies within [the] cold chain.
“This investment underscores our dedication to supporting exceptional high-growth healthcare companies that assist in bringing life-saving medicines to patients across the globe.”
The collaboration also involves Eutecma’s acquisition of Resolvision, a proprietary reuse technology employed at its refreshment centres.
Through this acquisition, Eutecma intends to broaden its global presence and enhance its offerings in the cold chain packaging sector.
The partnership is anticipated to further promote sustainable practices within the pharmaceutical industry.
Eutecma co-founder Florian Zeilfelder said: “We have successfully created innovative and sustainable cold chain solutions that have proven themselves with well-known pharmaceutical customers.
“Our work with GPP will advance that mission so we can strategically expand our reach, especially in the US and other geographies around the world.”
Healthcare investment company GPP is currently making new minority and majority private equity investments from GPP IV. The company manages about $1.5bn of capital via its private funds and public biotechnology equity strategy.
